Format

Send to

Choose Destination
J Vasc Surg. 2015 Jul;62(1):128-34. doi: 10.1016/j.jvs.2015.02.002. Epub 2015 Mar 12.

Use of the Flixene vascular access graft as an early cannulation solution.

Author information

1
Faculté de Médecine, Université Bordeaux, Bordeaux, France; Vascular Surgery Department, CHU de Bordeaux, Bordeaux, France. Electronic address: xavier.berard@chu-bordeaux.fr.
2
Vascular Surgery Department, CHU de Bordeaux, Bordeaux, France.
3
Vascular Surgery Department, CHUV de Lausanne, Lausanne, Switzerland.
4
Nephrology Department, CHU de Bordeaux, Bordeaux, France.
5
Faculté de Médecine, Université Bordeaux, Bordeaux, France; Vascular Surgery Department, CHU de Bordeaux, Bordeaux, France.
6
Faculté de Médecine, Université Bordeaux, Bordeaux, France; Nephrology Department, CHU de Bordeaux, Bordeaux, France.

Abstract

OBJECTIVE:

The primary end points of this study were safety and efficacy of early cannulation of the Flixene graft (Maquet-Atrium Medical, Hudson, NH). Secondary end points were complications and patency.

METHODS:

This is a prospective single-center nonrandomized study. Study data included patient characteristics; history of vascular access; operative technique; interval between implantation and initial cannulation; complications; and patency at 1 month, 3 months, and every 6 months. Patency rates were estimated by the Kaplan-Meier method.

RESULTS:

Between January 2011 and September 2013, a total of 46 Flixene grafts were implanted in 44 patients (27 men) with a mean age of 63 years. The implantation site was the upper arm in 67% of cases, the forearm in 11%, and the thigh in 22%. Seven grafts were never cannulated during the study period. Of the remaining 39 grafts, 32 (82%) were successfully cannulated within the first week after implantation, including 16 (41%) on the first day. The median interval from implantation to initial cannulation was 2 days (interquartile range, 1-3 days). The median follow-up was 223.5 days (interquartile range, 97-600 days). Five hematomas occurred, but only one required surgical revision. Primary assisted and secondary patency rates were 65% and 86%, respectively, at 6 months and 56% and 86%, respectively, at 1 year.

CONCLUSIONS:

This study suggests that cannulation of the Flixene graft within 1 week after implantation is safe and effective. Early cannulation avoids or shortens the need for a temporary catheter. One-year patency rates appeared to be comparable to those achieved with conventional grafts, but long-term follow-up and randomized controlled studies will be needed to confirm this finding.

PMID:
25770983
DOI:
10.1016/j.jvs.2015.02.002
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center